Reshaping the HIV treatment and prevention landscape
Influenza
Innovating to deliver greater protection, new ambition to double revenues in next decade
Significant burden of
disease remains¹
UP TO
~1bn
~3-5m
650,000
illnesses
annually
severe
illnesses
annually
deaths
£4.4bn²
market size in
2020
UP TO
£6.1bn²
market size by 2026
Sub-optimal existing solutions
Innovative technologies for superior efficacy
1. Innovative plant-based protein adjuvanted vaccine for 65+
segment*, Phase 3 data 2H 2023
2. Next generation mRNA vaccine**; Phase 3 data 2H 2025
- Multi-antigen construct
- Ambition of superiority vs standard of care
-
Potential for combinations with COVID &
other respiratory IDs
3. Transformational universal flu vaccine &
gsk
add-on mAb^ providing higher efficacy
1. 2018-2019 flu season data from the Centers for Disease Control and Prevention; Zhou et al. Clinical Infectious Diseases. 2012:54:1427-1436. 2. Evaluate Pharma March'21.
*GSK & Medicago collaboration agreement includes clinical supply of AS03 for development of an adjuvanted flu vaccine targeting the 65-plus age group; this vaccine is currently in phase I/II; phase III read out in 2H2023. The companies are in
discussion regarding details of a commercialisation agreement; **in collaboration with CureVac; ^in collaboration with Vir.
IDs infectious diseases
Flu ambition uses 2020 base.
68View entire presentation